In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, discusses how real-time data access is helping biotechs accelerate trial timelines, ensure ...

The Phase I/II trial will evaluate the safety and early efficacy of ABT-301 in combination with tislelizumab and bevacizumab ...

VX-993 failed to demonstrate superior efficacy over existing NaV1.8 inhibitors, leading to its discontinuation as monotherapy for acute pain. The trial showed that hydrocodone bitartrate/acetaminophen ...

Clinical trial failure insurance is turning biotech’s most costly risk into a manageable asset, opening new pathways for funding and innovation.

Clinical trial failure insurance is turning biotech’s most costly risk into a manageable asset, opening new pathways for funding and innovation.

Managing Director at NFP ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

In this video interview, Michael Miller, chief operating officer at Quanterix, discusses how biopharma companies—especially ...

The FDA’s green light for a Phase II trial (JSKN003-202) of JSKN003 accelerates efforts to address platinum-resistant ovarian ...

In this video interview, Michael Miller, chief operating officer at Quanterix, highlights neurology and oncology as two ...

New statistical frameworks such as net treatment benefit offer a multidimensional approach to evaluating efficacy, safety, ...

In this video interview, Michael Miller, chief operating officer at Quanterix, discusses how the use of biomarkers is ...